Google donates $8.5M for data, AI projects To view this email as a web page,
click here Novavax adds antigens to COVID-19 production pact with Indian vaccines giant Defining COVID-19 immunity: CDC, EU researchers tap Siemens Healthineers to help standardize antibody tests Healthcare roundup: Google donating $8.5M to COVID-19 data analytics, AI projects Biopharma roundup: AZ cleared to test shot in more Brazilian patients; global vaccination push could take up to 5 years, SII chief says PPD ups its revenue guidance after riding the tumultuous COVID-19 wave MDLive banks $50M equity investment to scale up telehealth services CMS planning to fully rely on encounter data for Medicare Advantage risk adjustment in 2022 Featured Story | By Kyle Blankenship Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast, however, and Novavax is now expanding one of its key manufacturing deals to aid the cause. read more |
| |
|---|
|
Top Stories By Conor Hale The project will help define the proper concentrations of antibodies necessary for a test to determine whether a person is immune to COVID-19. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner AstraZeneca won the OK the test its shot in 5,000 additional Brazilian subjects. Global vaccination efforts may take up to five years, the Serum Institute's Adar Poonawalla said. South Korea will spend $146 million to lock down vaccines for 60% of its population. Plus, researchers are developing treatments to strike COVID-19 in the nose. read more By Ben Adams PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares. read more By Heather Landi Riding the wave of investor interest in virtual care, MDLive banked a $50 million crossover equity investment led by Sixth Street Growth. Find out why CEO Charles Jones believes competitor Teladoc's blockbuster deal will spur more consolidation in the market, including acquisition opportunities for his own company. read more By Paige Minemyer CMS said it plans to begin in 2022 using solely encounter data to calculate risk adjustment in Medicare Advantage and Part D. read more |
|
